OX40 signaling is involved in the autoactivation of CD4+CD28− T cells and contributes to the pathogenesis of autoimmune arthritis by Juean Jiang et al.
RESEARCH ARTICLE Open Access
OX40 signaling is involved in the
autoactivation of CD4+CD28− T cells and
contributes to the pathogenesis of
autoimmune arthritis
Juean Jiang1†, Cuiping Liu1†, Mi Liu1, Yu Shen1, Xiaohan Hu1, Qin Wang1, Jian Wu1, Min Wu2, Qi Fang1*
and Xueguang Zhang1*
Abstract
Background: CD4+CD28− T cells exhibit autoreactive potential in autoimmune disorders, including rheumatoid
arthritis (RA). It is not well known which costimulator functions as an alternative second signal in the activation of
this subset after CD28 expression is downregulated. Tumor necrosis factor receptor superfamily member OX40 is a
key costimulator in the activation of T cells. The aim of this study was to investigate the costimulatory effects of
OX40 on CD4+CD28− T cells in autoimmune arthritis.
Methods: Clinical samples were collected from patients with RA and control subjects. Collagen-induced arthritis
(CIA) was induced with collagen type II (CII) in DBA/1 mice. The CD4+CD28−OX40+ T-cell subset and its cytokine
production were detected by flow cytometry. After T-cell purification, adoptive transfer was performed in CIA mice.
The regulatory role of OX40 was determined by blocking experiments in vitro and in vivo.
Results: OX40 and OX40L were abnormally expressed in patients with RA and CIA mice. Further analysis showed
that CD4+CD28−OX40+ T cells accumulated in patients with RA and in animal models. These cells produced higher
levels of proinflammatory cytokines and were closely correlated with the clinicopathological features of the affected
individuals. Adoptive transfer of CII-specific CD4+CD28−OX40+ T cells remarkably aggravated arthritic development
and joint pathology in CIA mice. Moreover, OX40 blockade significantly reduced the proinflammatory responses
and ameliorated arthritis development.
Conclusions: OX40 acts as an alternative costimulator of CD4+CD28− T cells and plays a pathogenic role in
autoimmune arthritic development, suggesting that it is a potential target for immunomodulatory therapy of RA.
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Background
Rheumatoid arthritis (RA) is a type of symmetric polyarti-
cular arthritis, and T cell-mediated autoimmune responses
to the articular synovium play a central role in the patho-
genesis of RA [1, 2]. A marked accumulation of CD4+ T
cells that lack CD28 expression is observed in patients
with RA [3]. CD4+CD28− T cells are autoreactive and
could be regarded as effector memory T cells [4]. T-cell
activation requires antigen recognition along with a
second signal delivered by interactions between the
costimulatory receptor on T cells and its ligands on
antigen-presenting cells (APCs) [5]. Costimulatory mol-
ecules, including B7/CD28 and tumor necrosis factor
(TNF)/tumor necrosis factor receptor (TNFR) super-
family members, are critical in antigen-specific T-cell
responses. The absence of a second signal results in anergy
and programmed cell death [6, 7]. However, loss of CD28
does not induce apoptosis in CD4+ T cells of patients with
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RA, suggesting that CD28-independent costimulatory path-
ways are involved in T-cell activation.
OX40 (CD134) and its ligand OX40L (CD252) are mem-
bers of the TNF/TNFR superfamily. OX40 (TNFR super-
family member 4, TNFRSF4) is predominantly expressed by
activated T cells, whereas the primary source of OX40L
(TNF superfamily member 4, TNFSF4) is likely to be APCs.
OX40 ligation augments the effector differentiation and the
survival of memory T cells. The roles of OX40 and OX40L
have been examined in most well-established autoimmune
models [8, 9]. Although TNFSF4 polymorphisms were
shown not to be linked with RA susceptibility [10],
blockade of OX40/OX40L in collagen-induced arthritis
(CIA) mice dramatically ameliorated disease severity
[11, 12]. This indicates that OX40 signal plays a critical
role in the development of autoimmune arthritis. As an
enhancer of effector memory T cells, OX40 may not be
an initiator, but may be an accelerator, in the pathogenesis
of RA. Association of OX40 expression with arthritis
development should be further investigated. Meanwhile,
whether OX40 signal is involved in the activation of
CD4+CD28− T cells in RA should be clarified.
In view of this, potential correlations were analyzed
between the CD4+CD28−OX40+ T-cell subset and
clinicopathological characteristics of affected individ-
uals among patients with RA and CIA mice. After cell
sorting, the arthritis-associated pathogenic role of
CD4+CD28−OX40+ T cells was investigated. Moreover,
using OX40 blockade in vitro and in vivo, we revealed




A total of 71 patients with RA diagnosed according to
the 2010 rheumatoid arthritis classification criteria were
recruited [13]. Additionally, 44 sex- and age-matched
patients with osteoarthritis (OA) and 47 healthy volun-
teers healthy controls (HCs) were included as control
subjects. All subjects were recruited from the Third Af-
filiated Hospital of Soochow University, Jiangsu, China.
Disease activity was evaluated according to the 28-joint
Disease Activity Score (DAS28). The level of disease ac-
tivity could be interpreted as rheumatoid arthritis with
low disease activity (Lo-RA), rheumatoid arthritis with
moderate disease activity (Mo-RA), rheumatoid arthritis
with high disease activity (Hi-RA), or rheumatoid arth-
ritis with remission (Re-RA), according to the European
League Against Rheumatism criteria [14]. Disease stages
included early and late RA on the basis of criteria for
early RA [15]. Nine patients with RA received metho-
trexate (MTX; Shanghai Sine Pharmaceutical Laborator-
ies Co., Shanghai, China) therapy (10 mg/week for
20 weeks by oral administration). None of the patients
had received immunosuppressive drugs within 1 year be-
fore the study period. Peripheral blood (PB) and synovial
fluid (SF) samples were obtained from subjects after in-
formed consent was provided according to a protocol ap-
proved by the local ethics committee of Soochow
University. Sampling was completed in accordance with
the guidelines of the local institutional review boards.
Data about the patients and HCs are presented in supple-
mentary figures and tables (Additional file 1: Table S1).
CIA induction and corticosteroid treatment
Male DBA/1 mice at 8–10 weeks of age were obtained
from the Shanghai Laboratory Animal Center and were
maintained in a specific pathogen-free animal facility at
Soochow University. All animal experiments conducted
in this study were approved by the University Committee
on the Use of Live Animals in Teaching and Research at
our institution. Male DBA/1 mice were immunized intra-
dermally at the base of the tail with 200 μg of bovine
collagen type II (CII; Chondrex, Redmond, WA, USA) dis-
solved in 100 μl of 0.05 M acetic acid and mixed with an
equal volume of complete Freund’s adjuvant containing
heat-killed Mycobacterium tuberculosis (H37Ra strain,
4 mg/ml; Chondrex). Three weeks later, animals were
reimmunized with 200 μg of CII emulsified in incomplete
Freund’s adjuvant (Chondrex). Mice were scored for clin-
ical signs as follows (per paw): 0, paws with no swelling; 1,
paws with swelling of finger joints or focal redness; 2,
paws with mild swelling of the wrist or ankle joints; 3,
paws with severe swelling of the entire paw; and 4, paws
with deformity or ankylosis. CIA mice were grouped into
acute collagen-induced arthritis (A-CIA) and chronic
collagen-induced arthritis (C-CIA) stages according to the
criteria described by Thornton et al. [16]. On day 35 after
the first immunization, dexamethasone (Dex; Tianjin
Pharmaceutical Jiaozuo Co., Tianjin, China) was intraperi-
toneally injected for 7 days, including low dose (L-dose,
0.5 mg/kg/day), high dose (H-dose, 2 mg/kg/day), and a
PBS control.
Sample preparation and flow cytometry
For PB samples, the fluorochrome-labeled monoclonal
antibodies (mAbs) antihuman CD4, CD28, and OX40
were added to 80 μl of whole blood before erythrocyte
lysis was performed. Synovial fluid mononuclear cells
(SFMCs) were isolated after SF samples were treated
with hyaluronidase (10 μg/ml; Sigma-Aldrich, St. Louis,
MO, USA). The mAbs described above were added to
100-μl SFMC suspensions (2 × 106 cells/ml). For CIA
mice, fluorochrome-labeled antimouse mAbs were added
to 100-μl splenocyte suspensions (1 × 106 cells/ml). Cells
were incubated and evaluated using a COULTER EPICS
XL flow cytometer (Beckman Coulter, Brea, CA, USA).
The gating strategy for the CD4+CD28−OX40+ T-cell
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subset is described in supplementary figures and tables
(Additional file 1: Fig. S1). For intracellular staining,
peripheral blood mononuclear cells (PBMCs; 3 × 106/
well) were stimulated with phorbol 12-myristate 13-acetate
(PMA, 50 ng/ml; eBioscience, San Diego, CA, USA) and
ionomycin (1 μg/ml; eBioscience). Antihuman CD4, CD28,
and OX40 mAbs were added before fixation and
permeabilization, followed by the addition of phycoerythrin
(PE)-cyanine 7 (Cy7)-conjugated antihuman interferon
(IFN)-γ (clone 4S.B3; BioLegend, San Diego, CA, USA),
interleukin (IL)-4 (clone MP4-25D2; BioLegend), or IL-
17A (clone BL168; BioLegend) mAbs. Intracellular
cytokine production was assessed using an FC 500
analyzer (Beckman Coulter). Information about all anti-
bodies is provided in supplementary figures and tables
(Additional file 1: Table S2).
Adoptive transfer of CD4+CD28−OX40+ T cells
On day 28 after the second immunization, CIA mice were
killed, and mononuclear splenocytes were stimulated in vitro
with CII (30 μg/ml) for 72 h. CD4+ T cells were selected
from mononuclear splenocytes using CD4+ microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) to over 97%
purity. After CD28 and OX40 antimouse mAbs were added,
T-cell subsets were sorted using a FACSAria™ II cell sorter
(BD Biosciences, Franklin Lakes, NJ, USA). Sorted T cells
(1 × 106 cells in 200 μl of PBS) were injected intravenously
into CIA mice on day 0 after the second immunization.
After being fixed and decalcified, mouse ankles were embed-
ded in paraffin and sectioned at 5-μm thickness before being
stained with hematoxylin and eosin (H&E).
OX40/OX40L blockage in vitro
On day 28 after the second immunization, mononuclear
splenocytes (1 × 105/well) of CIA mice were seeded onto
96-well tissue culture plates (Corning, Corning, NY,
USA) in 10% FBS/RPMI 1640 medium and stimulated
with CII (30 μg/ml) or anti-CD3 mAb (clone 145-2C11,
1 μg/ml; BioLegend) in the presence of antimouse OX40L
mAb (clone RM134L; BioLegend). Rat immunoglobulin G
(IgG) (clone RTK4530; BioLegend) was added as a control.
After 72 h of incubation, cell proliferation was determined
using a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories,
Mashikimachi, Japan). Supernatant cytokine levels were
assessed using a mouse Th1/Th2/Th17 cytokine kit (BD
Biosciences) according to the manufacturer’s instructions.
OX40/OX40L blockade in vivo
On days 1–4 after the second immunization, randomized
mice were injected intraperitoneally with antimouse
OX40L mAb (100 μg/mouse/day) or IgG as controls. In
another experiment, mice with similar arthritis scores
were treated with anti-OX40L mAb or IgG on days 14–17
after the second immunization. On days 28 and 39 after
anti-OX40L mAb early treatment, mononuclear splenocytes
(1 × 105/well) were stimulated with CII (30 μg/ml) for 72 h.
Cell proliferation, supernatant cytokine levels, and
intracellular staining were evaluated as described above.
The PE-Cy7-conjugated antimouse mAbs used were as
follows: IFN-γ (clone XMG1.2), IL-4 (clone 11B11),
TNF-α (clone MP6-XT22), and IL-17A (clone TC11-
18H10.1) (all from BioLegend).
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics for Windows version 20.0 software (IBM, Armonk,
NY, USA). All quantitative data are presented as the
mean ± SD. Student’s t test or nonparametric Mann-
Whitney U test was used for independent samples. A
paired-samples t test or a nonparametric Wilcoxon
signed-rank test was performed for paired samples. For
multiple comparisons, one-way analysis of variance or the
Kruskal-Wallis test was performed. A Spearman’s r value
was calculated for correlation analyses. A P value less than
0.05 was considered to denote a significant difference.
Results
Abnormal expression of OX40 and OX40L in patients with
RA and CIA mice
Flow cytometric analysis demonstrated that OX40
expression on CD4+ T cells in PB samples was more
frequent in patients with RA than in patients with OA
or HCs (9.30 ± 3.14% vs 7.55 ± 3.26%, 6.90 ± 2.64%,
respectively, P = 0.008) (Fig. 1a and b). Expression of
OX40L on CD14+ monocytes (P = 0.034) and CD19+ B
cells (P < 0.001) also increased significantly in PB sam-
ples of patients with RA (Fig. 1a and b). In animal
models, we found that OX40 and OX40L expression
in spleen samples of CIA mice increased significantly
compared with normal control mice (NC) (all P < 0.001)
(Fig. 1c and d). Furthermore, SF samples exhibited in-
creased expression of OX40 and OX40L in patients with
RA (all P < 0.05) (Fig. 1e and f).
Accumulation of CD4+CD28−OX40+ T cells in patients with
RA and CIA mice
Flow cytometric assessments of PB samples revealed a
higher percentage of CD4+CD28− T cells in patients with
RA than in patients with OA and HCs (P= 0.021) (Fig. 2a).
Further analysis showed that OX40 expression on CD4
+CD28− T cells was significantly increased in PB samples
from patients with RA compared with those from control
subjects (10.14 ± 3.98% vs 7.83 ± 4.28%, 6.91 ± 3.13%,
respectively; P= 0.006) (Fig. 2b). Meanwhile, OX40 expres-
sion on CD4+CD28+ T cells was also elevated in PB samples
of patients with RA compared with that in control sub-
jects (P = 0.004) (Fig. 2c). Additionally, enrichment of
CD4+CD28−, CD4+CD28−OX40+, and CD4+CD28+OX40+
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Tcells could be observed in SF samples from patients with
RA (all P < 0.05) (Fig. 2d and e). However, the percentages
of CD4+CD28−OX40+ and CD4+CD28+OX40+ T cells
were comparable in both PB and SF samples of patients
with RA (both P > 0.05). Similar to patients with RA, a
higher percentage of CD4+CD28−, CD4+CD28−OX40+,
and CD4+CD28+OX40+ T-cell subsets could be observed
in spleen samples of CIA mice than in NCs (all P < 0.001)
(Fig. 2f–h). Moreover, CD4+CD28− T cells displayed
enhanced CD45RO expression compared with CD4+CD28+
T cells in PB samples of patients with RA (Fig. 2i). Intracel-
lular staining revealed that PMA/ionomycin-stimulated
CD4+CD28−OX40+ T cells produced more IFN-γ (P =
0.026) and IL-4 (P = 0.042) in PB samples of patients with
RA than those in control subjects. For CD4+CD28−OX40−
or CD4+CD28+OX40+ T cells, just IFN-γ (P = 0.036) or
IL-4 (P = 0.044) secretion was increased in patients with
RA, respectively. No significant difference was observed in
Fig. 1 Expression of OX40 and its ligand OX40L in patients with RA and CIA mice. a, c, e Flow cytometry detection of OX40 and OX40L
expression on immune cells in (a) PB or (e) SF samples of patients with RA, patients with OA, and HCs or (c) the spleen samples of CIA and NC
mice. Data indicate the mean (%) of OX40+ or OX40L+ cells among gated cells. Solid lines indicate specific staining of OX40L, and gray shading
represents isotype controls (scatter diagrams of isotype controls are not shown). b Percentages of CD4+OX40+, CD14+OX40L+, and CD19+OX40L+
cells in the PB samples of patients with RA (n = 71), patients with OA (n = 44), and HCs (n = 47). d Percentages of CD4+OX40+, CD11b+OX40L+,
and CD19+OX40L+ cells in the spleen samples of CIA (n = 40) and NC (n = 30) mice. f Percentages of CD4+OX40+, CD14+OX40L+ and tissue OX40L+
cells in the SF samples of patients with RA (n = 10) and patients with OA (n = 10). Bars indicate mean ± SD; * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not
significant. CIA Collagen-induced arthritis, HC Healthy control subject, NC Normal control mice, OA Osteoarthritis, PB Peripheral blood, RA Rheumatoid
arthritis, SF Synovial fluid
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Fig. 2 The CD4+CD28−OX40+ T-cell subset in patients with RA and CIA mice. a Percentages of CD4+CD28− T cells in the PB samples of patients with RA
(n= 71), patients with OA (n= 44), and HCs (n= 47). b Percentages of CD4+CD28−OX40+ T cells in the PB samples of patients with RA and control subjects.
c Percentages of CD4+CD28+OX40+ T cells in the PB samples of patients with RA and control subjects. d Flow cytometric analyses of CD4+CD28−OX40+
T cells in SF samples of patients with RA and patients with OA (isotype controls not shown). Values indicate the mean (%) of T-cell subsets. e Percentages
of CD4+CD28−, CD4+CD28−OX40+, and CD4+CD28+OX40+ T cells in the SF samples of patients with RA (n= 5) and patients with OA (n= 5). f, g, and
h Percentages of CD4+CD28− (f), CD4+CD28−OX40+ (g), and CD4+CD28+OX40+ (h) T cells in the spleen samples of CIA (n= 40) and NC (n= 30) mice.
i Expression levels of CD45RA and CD45RO on CD4+CD28− and CD4+CD28+ T cells in the PB samples of patients with RA (n= 5). j Cytokine production
levels of CD4+CD28−OX40+ and the other T-cell subsets in PB samples of patients with RA (n = 5) and control subjects (n= 5). Each data point represents
an individual subject; horizontal lines represent the mean; bars show mean ± SD; * P< 0.05, ** P< 0.01, *** P< 0 .001, ns = not significant. CIA Collagen-
induced arthritis, HC Healthy control subject, NC Normal control mice, OA Osteoarthritis, PB Peripheral blood, RA Rheumatoid arthritis, SF Synovial fluid
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cytokine production of CD4+CD28+OX40− T cells be-
tween patients with RA and control subjects (Fig. 2j).
CD4+CD28−OX40+ T-cell subsets closely correlate with
clinicopathological characteristics of patients with RA and
CIA mice
The DAS28 was used to evaluate arthritic activity,
which was positively correlated with the percentage of
CD4+CD28−OX40+ T cells in PB samples of patients
with RA (r = 0.515, P < 0.001) (Fig. 3a). Further analysis
showed significant differences among the percentages
of CD4+CD28−OX40+ T cells in PB samples of patients
with Re-RA (5.94 ± 2.24%), Lo-RA (9.68 ± 2.31%, P =
0.001), Mo-RA (11.14 ± 3.12%, P < 0.001), and Hi-RA
(12.65 ± 4.47%, P < 0.001) (all vs Re-RA) (Fig. 3b). MTX
significantly relieved arthritis activity and reduced the
percentage of CD4+CD28−OX40+ T cells in PB samples
of patients with RA (5.93 ± 1.80% vs 7.74 ± 2.54% post-
therapy vs pretherapy, P = 0.038) after 16 weeks of treat-
ment. However, follow-up in the 32nd week showed that,
with arthritis relapse, the percentage of this T-cell subset
was higher than in the 16th week (8.10 ± 1.62% vs
5.93 ± 1.80%, P = 0.008) (Fig. 3c). In different clinical
stages, patients with Late-RA exhibited a higher per-
centage of CD4+CD28−OX40+ T cells in PB samples
than patients with Early-RA (P = 0.002) (Fig. 3d, left).
Additionally, there was a significant difference in the
percentage of this subset in PB samples between patients
with rheumatoid arthritis with extraarticular manifesta-
tions (Extra-RA) and patients with rheumatoid arthritis
with limited joint manifestations (Limited-RA) (P = 0.036)
(Fig. 3d, right). As an important clinical indicator, the
Fig. 3 Correlations between CD4+CD28−OX40+ T cells and clinicopathological characteristics. a Correlation between DAS28 and the percentages
of this subset (n = 71) in patients with RA. b Subset percentages of patients with Re-RA (n = 13), Lo-RA (n = 17), Mo-RA (n = 27), and Hi-RA (n = 14).
c Changes of this subset in patients with RA treated with MTX (n = 9). d Percentages of this subset in patients with Early-RA (n = 32), Late-RA
(n = 39), Extra-RA (n = 18), and Limited-RA (n = 53). e Correlation between RF levels and percentages of this subset (n = 71) in patients with RA.
f Correlation between the arthritis scores of CIA mice and the percentages of this subset (n = 40). g Percentages of this subset in A-CIA (n = 19) and C-
CIA (n = 21) mice. h Subset percentages in CIA mice treated with the L-dose (n = 13) or H-dose (n = 13) of Dex or PBS (n = 13). i Changes of this subset
after Dex treatment. Each data point represents an individual subject; horizontal lines represent means; the r value indicates Spearman’s correlation
coefficient; * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant. A-CIA Acute collagen-induced arthritis, CIA Collagen-induced arthritis, C-CIA Chronic
collagen-induced arthritis, Dex Dexamethasone, Extra-RA Rheumatoid arthritis with extraarticular manifestations, H-dose High dose, Hi-RA Rheumatoid
arthritis with high disease activity, L-dose Low dose, Limited-RA Rheumatoid arthritis with limited joint manifestations, Lo-RA Rheumatoid arthritis with
low disease activity, Mo-RA Rheumatoid arthritis with moderate disease activity, MTX Methotrexate, RA Rheumatoid arthritis, Re-RA Rheumatoid arthritis
with remission, RF Rheumatoid factor
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levels of rheumatoid factor (RF) were positively correlated
with the percentage of CD4+CD28−OX40+ T cells in PB
samples of patients with RA (r = 0.288, P = 0.015) (Fig. 3e).
In spleen samples of animal models, a positive correlation
was found between arthritis scores and the percentages of
the CD4+CD28−OX40+ T-cell subset (r = 0.5354,
P = 0.0004) (Fig. 3f). During different phases of disease,
the number of CD4+CD28−OX40+ T cells was increased
in spleen samples of C-CIA mice compared with that in
A-CIA mice (Fig. 3 g). Both L-dose and H-dose Dex
markedly alleviated arthritic development in CIA mice
(supplementary figures and tables in Additional file 1:
Fig. S2) and reduced the percentages of CD4+CD28
−OX40+ T cells in spleen samples (Fig. 3 h). Three weeks
after low doses of Dex administration, the percentage of
CD4+CD28−OX40+ T cells in spleen samples of CIA
mice approximated that of the control levels (Fig. 3i).
Adoptive transfer of CD4+CD28−OX40+ T cells aggravated
arthritic progression in CIA mice
Arthritic onset in CIA mice that received transfer with
CD4+CD28−OX40+ T cells occurred much earlier, and the
arthritis scores in these mice were much higher than those
in control CIA mice (8.55 ± 3.17 vs 3.48 ± 2.12, P < 0.001)
(Fig. 4c). Meanwhile, arthritis onset and scores in CIA mice
that received transfer with CD4+CD28−OX40− T cells
also showed a significant difference from those in con-
trol CIA mice (6.57 ± 2.47 vs 3.48 ± 2.12, P < 0.001)
(Fig. 4a). Although CD4+CD28+OX40− or CD4+CD28
+OX40+ T-cell transfer slightly accelerated early arth-
ritic development in CIA mice, these scores did not reach
significance compared with control CIA mice (P = 0.718
and P = 0.102, respectively) (Fig. 4b and d). Furthermore,
among the four T-cell subsets transferred to CIA mice,
CD4+CD28−OX40+ T cells displayed the most significant
pathogenic role in arthritis development compared with
CD4+CD28−OX40− (P = 0.011), CD4+CD28+OX40− (P
< 0.001), and CD4+CD28+OX40+ (P < 0.001) T cells. Se-
vere synovial and periarticular inflammation with ab-
normal narrowing of the joint space was observed in
H&E staining of CIA mice transferred with CD4+CD28
−OX40+ T cells. Similarly, micro-computed tomography re-
vealed the most serious bone erosion in CIA mice that re-
ceived transfers with CD4+CD28−OX40+ T cells compared
with those in control CIA mice (Fig. 4e).
OX40 blockade significantly inhibited proinflammatory
responses in vitro
In splenocytes stimulated with CII, OX40L-blocking
antibodies at 2.5 μg/ml (P = 0.006), 5.0 μg/ml (P < 0.001),
and 10.0 μg/ml (P < 0.001) displayed inhibitory effects
on cell proliferation compared with IgG controls (Fig. 5a,
left). Simultaneously, antibodies at 5.0 μg/ml (P = 0.002)
and 10.0 μg/ml (P < 0.001) exhibited depressing effects
on the proliferation of splenocytes activated by CD3
stimuli (Fig. 5a, right). Further studies showed that ap-
plying the blocking antibody at 5.0 μg/ml remarkably
reduced the cytokine secretion of CII-stimulated sple-
nocytes, including IFN-γ (26.86 ± 8.88 pg/ml vs 41.96 ±
11.23 pg/ml, P = 0.021), IL-4 (10.65 ± 2.85 pg/ml vs
18.67 ± 5.75 pg/ml, P = 0.005), and TNF-α (190.59 ±
90.11 pg/ml vs 371.86 ± 160.72 pg/ml, P = 0.021) (all vs
IgG controls). However, levels of IL-10 were elevated
(P = 0.046), and the secretion of IL-2, IL-6, and IL-17A
were not significantly different from those in the IgG
controls (all P > 0.05) (Fig. 5b). Additionally, OX40
blockade showed similar effects on cytokine production
in splenocytes stimulated with CD3 (Fig. 5c).
OX40 blockade ameliorated arthritic progression in CIA mice
Early treatment starting on day 1 after the second
immunization indicated that OX40 blockade in vivo de-
layed arthritis onset and reduced the arthritis scores of CIA
mice compared with IgG controls (P = 0.013) (Fig. 6a). Cor-
respondingly, late treatment starting on day 14 after the
second immunization also evidently alleviated arthritis de-
velopment (P = 0.008) (Fig. 6b). Further studies demon-
strated that OX40 blockade in vivo reduced cell
proliferation (P = 0.037) (Fig. 6c) and cytokine secretion, in-
cluding IFN-γ (P = 0.025), IL-4 (P = 0.025), and TNF-α (P =
0.037), by CII-stimulated splenocytes (Fig. 6d). Accordingly,
in vivo changes in IL-10, IL-2, IL-6, and IL-17A levels were
consistent with the in vitro experiment (Fig. 6d). Intracellu-
lar staining showed that OX40 blockade in vivo significantly
suppressed cytokine secretion by CD4+CD28−OX40+ T
cells, including IFN-γ (59.38 ± 11.78% vs 74.10 ± 10.39%, P
= 0.028), TNF-α (76.88 ± 8.77% vs 90.84 ± 7.43%, P = 0.028),
and IL-4 (9.11 ± 3.12% vs 16.01 ± 3.89%, P = 0.016) (all vs
IgG controls). However, the levels of IL-17A were not sig-
nificantly different (Fig. 6e). For CD4+CD28+OX40+ T
cells, TNF-α and IL-4 were reduced by OX40 blockade
(both P < 0.05). With regard to CD4+CD28−OX40− and
CD4+CD28+OX40− T cells, OX40 blockade had no impact
on the secretion of IFN-γ, TNF-α, IL-4, and IL-17A com-
pared with IgG controls (all P > 0.05) (Fig. 6e).
Discussion
Recently, the self-activation mechanisms of CD4+CD28−
T cells have been explored, including allelic associations
[17], cytokine production [18, 19], cell receptor stimula-
tion [20, 21], and DNA methylation [22, 23]. However,
in the absence of CD28, which costimulatory molecules
mediate the second signal is not yet well known. Re-
searchers in a recent study reported that OX40 expres-
sion was upregulated on CD4+CD28− T cells in patients
with acute coronary syndrome and that the secretion of
IFN-γ and TNF-α was suppressed by OX40 blockade
[24]. However, whether abnormal OX40 signaling is
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involved in the self-responses of CD4+CD28− T cells in
patients with RA remains unclear. In this study, a
CD4+CD28−OX40+ T-cell subset was established to
be clinicopathologically significant, and its autoreactiva-
tion and pathogenicity were demonstrated in patients with
RA and CIA mice. Additionally, the regulatory roles of
OX40 signaling in CD4+CD28− T cells were verified in
vitro and in vivo.
In accord with previous studies [25], abnormal expres-
sion of OX40 in patients with RA and CIA mice suggested
that an OX40 costimulatory signal was involved in the
pathological development of autoimmune arthritis. Fur-
ther upregulated expression of OX40 in SF of patients
with RA implied that OX40 signal may promote abnormal
activation of autoreactive T cells after migration of CD4+
T into the inflammatory microenvironment. In patients
with RA, enhanced OX40 expression was observed not
only on CD4+CD28− but also on CD4+CD28+ T cells.
OX40 expression levels did not depend on CD28 expres-
sion in RA, suggesting that OX40 costimulated T cells in a
CD28-independent way. In addition, CD4+CD28− T cells
with enhanced CD45RO expression suggested the charac-
teristics of memory T cells, and this population is enriched
in patients with RA, probably because of OX40 overex-
pression. Elevated levels of IFN-γ and IL-4 suggest that
CD4+CD28−OX40+ T cells may be involved in Th1/Th2
Fig. 4 Adoptive transfer in CIA mice. Passive CIA was induced by intravenous transfer of sorted CD4+CD28−OX40− (a, n = 4), CD4+CD28+OX40−
(b, n = 4), CD4+CD28−OX40+ (c, n = 5), or CD4+CD28+OX40+ (d, n = 4) T-cell subsets. CIA mice that received transfers with CD4+CD28−OX40− and
CD4+CD28−OX40+ T cells had aggravated arthritis development compared with control CIA mice (n = 4). CD4+CD28+OX40− and CD4+CD28+OX40
+ T cells did not significantly affect arthritis development compared with control CIA mice. The arthritis scores of different groups of recipient mice are
shown as the mean ± SD. e H&E histological stains (×200 original magnification) and micro-computed tomographic analysis of representative ankle
sections from the experiments shown in a, b, c, and d. CIA Collagen-induced arthritis, H&E Hematoxylin and eosin
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responses and help to produce autoantibody, such as RF
[26]. However, CD4+CD28−OX40− may just function in a
Th1 pathway, and for CD4+CD28+OX40+ T cells, a Th2
pathway may be involved. These results implied that
CD4+CD28−OX40+ T cells were distinct from the other
T-cell subsets and may exhibit specific characteristics in
autoimmune arthritis. Upon OX40 costimulation, ef-
fector differentiation and long survival may emerge in
memory CD4+CD28− T cells, which may increase disease
activity and lead to a protracted course of disease, as de-
scribed in another study [25]. As a consequence of OX40
overexpression, CD4+CD28− T cells may differentiate di-
versely in response to multiple autoantigens, suggesting
extraarticular manifestations, as mentioned in previous
studies [3, 27]. Immunosuppressive agents regulate im-
mune responses by changing the expression and func-
tion of costimulatory molecules [28, 29], and this
regulatory role could be effectively reversed by OX40-
mediated costimulatory signals [30]. Reduced OX40
signals by MTX or Dex treatment may suppress the auto-
activation of CD4+CD28− T cells and lead to arthritis re-
mission. However, arthritis relapses after medicine
withdrawal suggest that new specific approaches for ther-
apy must be explored.
In adoptive transfer assays, although similar arthritis
scores were observed on day 34 in the duration curves,
CD4+CD28−OX40+ T cells demonstrated a more
powerful pathogenic role than the CD4+CD28−OX40−,
CD4+CD28+OX40−, and CD4+CD28+OX40+ T cells in
both early (days 1–33) and late (days 35–64) arthritis.
This finding indicates that, in early arthritis, activation
of CD4+CD28−OX40+ T cells occurs in a short-lived
effector- and autoantigen-dependent manner but prob-
ably acts in a long-lived memory- and autoantigen-
independent fashion in late arthritis, in agreement with
the OX40 properties described by Croft [8, 9]. Probably
owing to natural killer cell or chemokine receptors
expressed on CD4+CD28− T cells [20, 21], mice that
received transfers with CD4+CD28−OX40− T cells
exhibited deteriorated arthritis progression, especially
in early arthritis. On one hand, this meant that, in early
arthritis, additional mechanisms were involved in acti-
vation of CD4+CD28− T cells, except for OX40 costi-
mulation, On the other hand, long-lived memory
characteristics of OX40 [8, 9] may take effects in late
arthritis. Autoantigen-specific CD4+CD28−OX40+ T
cells resulted in persistent autoimmune injuries and
protracted joint damage. However, the absence of
OX40 markedly reduced the survival of memory T cells,
and late arthritis development was alleviated in the
mice that received transfers with CD4+CD28+OX40− T
cells. Recent studies showed that OX40 costimulatory
signals promoted differentiation of effector T lympho-
cytes in a CD28-independent way [31] and that “super-
stimulation” of combined CD28 and OX40 did not
outperform CD28 by itself [32]. Additionally, the pres-
ence of OX40 may neutralize costimulation of CD28
[33], which may impair arthritis pathogenic roles of
Fig. 5 OX40/OX40L blockade in vitro. a Cell proliferation in the CII- or CD3-stimulated splenocytes of CIA mice in the presence of anti-OX40L
mAb (2.5 μg/ml, n = 19; 5.0 μg/ml, n = 19; 10.0 μg/ml, n = 19) or IgG controls (n = 19). b, c Cytokine secretion in the supernatants of CII-stimulated
(b) or CD3-stimulated (c) splenocytes from CIA mice in the presence of anti-OX40L mAb (5.0 μg/ml, n = 8) or in IgG controls (n = 8). Bars show
means ± SD; * P< 0.05, ** P< 0.01, *** P< 0.001. CIA Collagen-induced arthritis, CII Collagen type II, IgG Immunoglobulin G, mAb Monoclonal antibody
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CD4+CD28+OX40+ T cells. A distinct pathogenic role
has been further confirmed on the basis of different
characteristics of CD28− and CD28+ T cells [4]. The
robust pathogenicity of CD4+CD28− T cells may reflect
OX40 characteristics of costimulating memory T cells
in a CD28-independent manner, as described in a re-
port by Demirci et al. [34].
In vitro different time points resulted in findings in-
consistent with those of Yoshioka et al. [11], probably
because of the diverse roles of OX40 in short-lived ef-
fector and long-lived memory cells [8, 9]. In our study,
the blockade time point was day 28 after the second
immunization, whereas in the study by Yoshioka et al., it
was day 7. On day 7, OX40+ T cells may have occurred
in the absence of short-lived effector responses, whereas
OX40 memory characteristics may be generated on days
14–28. In vitro OX40 blockade on day 7 may have little
effect. On the basis of in vitro studies, early treatment
on days 1–4 in vivo showed results similar to those of
the studies by Yoshioka et al. [11] and Gwyer Findlay
et al. [12], probably owing to suppression of short-lived
effector responses of OX40+ T cells. However, inconsist-
ent with the findings of Yoshioka et al. [11], delayed
treatment on days 14–17 also distinctly ameliorated
Fig. 6 OX40/OX40L blockade in vivo. a, b Treatment with anti-OX40L mAb on days 1–4 (a, n= 6) (IgG, n= 8) and days 14–17 (b, n= 4) (IgG, n= 6) after
the second immunization ameliorated arthritis development in CIA mice. Arrows indicate the days of dosing. c Splenocytes from CIA mice treated with
anti-OX40L mAb (n= 6) demonstrated reduced proliferation in CII stimulation compared with those treated with IgG (n= 6). d Cytokine secretion in the
supernatants of splenocytes from CIA mice treated with anti-OX40L mAb (n= 6) or IgG controls (n= 6). e Cytokine production of CD4+CD28−OX40+ and
the other control T-cell subsets after the splenocytes from CIA mice treated with anti-OX40L mAb (n= 5) or IgG controls (n= 5) were stimulated with
PMA/ionomycin. Bars show mean ± SD; * P< 0.05, ** P< 0.01. CIA Collagen-induced arthritis, CII Collagen type II, IgG Immunoglobulin G, mAb
Monoclonal antibody
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arthritis symptoms, mainly owing to the different time
points. On day 14 (blockade time point in our study),
generation of memory T cells may be reduced by OX40
blockage, whereas short-lived effector responses resulting
from OX40 may have faded on day 7 (blockade time point
in study by Yoshioka et al.). Changes in cytokine levels fur-
ther corroborated the findings in analysis of human samples.
In the immunopathogenesis of RA, Th1 and Th2 responses
are involved in different phases [2]. As observed in transfer
assays, Th1/Th2-polarized CD4+CD28−OX40+ Tcells played
central roles in all phases of autoimmune arthritis. However,
CD4+CD28+OX40− and CD4+CD28+OX40+ T cells contrib-
uted to outcomes only in the early phases of the pathological
process. For CD4+CD28−OX40− T cells, although early
Th1 response aggravated arthritic development in an
OX40-independent way, progression faded in late-
phase arthritis.
Conclusions
A novel CD4+CD28−OX40+ T-cell subset was established
to be clinicopathologically significant, suggesting that
OX40 may act as a promising biomarker for RA. OX40
was characterized as an alternative costimulator for auto-
activation of CD4+CD28− T cells in autoimmune arthritis,
and OX40 blockade may represent an effective approach
for immunomodulatory therapy.
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